Role of p21 in prostaglandin A2-mediated cellular arrest and death

Cancer Research

Volumn 56, Issue 3, 1996, Pages 475-479

  Gorospe, Myriam ^a   Holbrook, Nikki J ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROSTAGLANDIN A2; PROTEIN P21;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL STRAIN 3T3; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; BASE SEQUENCE; CDC2-CDC28 KINASES; CELL COUNT; CELL CYCLE; CELL DEATH; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; FLOW CYTOMETRY; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES, ANTISENSE; PROSTAGLANDINS A; PROTEIN-SERINE-THREONINE KINASES; RATS; TUMOR CELLS, CULTURED;

EID: 0030024241     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
2. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B , Parsons, R., Trent, J. M., Lin, D , Mercer, W. E., Kinzler, K. W., and Vogelstein, B WAF-1, a potential mediator of p53 tumor suppression. Cell, 75. 817-825, 1993
3. 1 arrest Cell, 76: 1013-1023, 1994.
4. Jiang, H., Lin, J., Su, Z., Collart, F R., Huberman, E., and Fisher, P. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/ CIP1, expression in the absence of p53 Oncogene, 9: 3397-3406, 1994
5. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
6. 1 arrest and apoptosis. Cancer Res , 54: 1169-1174, 1994.
7. Canman, C. E., Gilmer, T M., Coutts, S. B., and Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev., 9: 600-611, 1995.
8. 2-induced growth inhibition. Biochem Biophys. Res. Commun., 139 808-815, 1986.
9. Kikuchi, Y., Kita, T., Hirata, J., Kuki, E., Nagata, I., and Fukushima, M Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins. Int. J. Immunopharmacol , 14: 105-110, 1992.
10. Kikuchi, Y., Kita, T., Miyauchi, M., Hirata, J., Sasa, H., Nagata, I , and Fukushima, M. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. J. Cancer Res. Clin. Oncol., 118: 453-457, 1992.
11. 1 arrest and preclinical results Ann. NY Acad. Sci., 744.161-165, 1993.
12. Sasaki, H., and Fukushima, M. Prostaglandins in the treatment of cancer. Anticancer Drugs, 5: 131-138, 1994.
13. 12-prostaglandin J2. Gynecol. Oncol., 41: 36-40, 1991.
14. Narumiya, S., and Fukushima, M. Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther., 239: 500-505, 1986
15. Bregman, M. D., Funk, C., and Fukushima, M. Inhibition of human melanoma growth by prostaglandin A, D, and J analogues. Cancer Res., 46: 2740-2744, 1986
16. 1-enriched HeLa S3 cells. J. Pharmacol. Exp. Ther., 245: 294-298, 1988.
17. 2 in nuclei J. Pharmacol Exp. Ther., 242: 306-311, 1987.
18. Santoro, M. G., Crisari, A., Benedeto, A., and Amici, C. Modulation of the growth of a human erythroleukemic cell line (K562) by prostaglandins: antiproliferatrve action of prostaglandin A. Cancer Res., 46: 6073-6077, 1986.
19. 2. Mol. Cell. Biol., in press, 1996.
20. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
21. 1 checkpoint does not decrease cell survival following DNA damage Cancer Res , 53: 4164-4168, 1993.
22. cdc2 in T lymphocytes. J Immunol., 149: 17-23, 1992.